-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
Atea Pharmaceuticals, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q2 2021 to Q3 2025.
- Atea Pharmaceuticals, Inc. Income Tax Expense (Benefit) for the quarter ending September 30, 2025 was $196K, a 13.3% decline year-over-year.
- Atea Pharmaceuticals, Inc. Income Tax Expense (Benefit) for the twelve months ending September 30, 2025 was $831K, a 20.8% decline year-over-year.
- Atea Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2024 was $925K, a 9.14% decline from 2023.
- Atea Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2023 was $1.02M.
- Atea Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2022 was -$3.59M, a 121% decline from 2021.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)